Despite considerable efforts to target KRAS mutations, modest success has been achieved due to the versatility of the structural conformation induced by mutations and the amount of upstream and downstream regulatory pathways, which can induce the development of tumours with multiple mechanisms of resistance to new therapies [8,19,56,60,61]. Here, KRAS is linked to neoplasm.